This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Daewoong Pharmaceutical Co., Ltd.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Innovations of Sung-Young Kim in Sodium Channel Blockers
Introduction
Sung-Young Kim is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of sodium channel blockers. His work is characterized by a focus on compounds that can be utilized in the prevention and treatment of related diseases.
Latest Patents
One of Sung-Young Kim's key patents is titled "Substituted benzenesulfonamides as sodium channel blockers." This invention relates to a compound represented by Chemical Formula 1, along with its pharmaceutically acceptable salts. The pharmaceutical composition comprising this compound or its salts can be effectively used for the prevention or treatment of sodium channel blocker-related diseases. This patent highlights his innovative approach to addressing medical challenges through chemical compounds.
Career Highlights
Sung-Young Kim is currently associated with Daewoong Pharmaceutical Co., Ltd., a prominent company in the pharmaceutical industry. His role at Daewoong Pharmaceutical has allowed him to further his research and development efforts in creating effective medical solutions. His dedication to innovation is evident in his patent work and contributions to the field.
Collaborations
Sung-Young Kim has collaborated with notable colleagues, including Hyung-Geun Lee and Il-Hwan Kim. These collaborations have likely enhanced the research and development process, leading to more comprehensive solutions in the pharmaceutical domain.
Conclusion
Sung-Young Kim's contributions to the field of sodium channel blockers exemplify the impact of innovative thinking in pharmaceuticals. His patent work and collaborations reflect a commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
